Apollomics Inc (APLM)

NASDAQ
Currency in USD
4.7350
+0.0150(+0.32%)
Real-time Data·
APLM Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
APLM is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.73504.8900
52 wk Range
4.470136.7500
Key Statistics
Edit
Prev. Close
4.625
Open
4.76
Day's Range
4.735-4.89
52 wk Range
4.4701-36.75
Volume
1.54K
Average Volume (3m)
24.5K
1-Year Change
-86.53%
Book Value / Share
4.41
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
APLM Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year
Show more

Apollomics Inc Company Profile

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways that is in Phase 1 dose escalation clinical trials to treat cancers within the brain. The company’s pipeline consists of cc product candidates, such as APL-501, APL-502, and APL-801. Its solutions include tumor inhibitors and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Compare APLM to Peers and Sector

Metrics to compare
APLM
Peers
Sector
Relationship
P/E Ratio
−0.1x−0.5x−0.5x
PEG Ratio
0.00−0.010.00
Price/Book
1.1x2.1x2.6x
Price / LTM Sales
26.6x12.0x2.9x
Upside (Analyst Target)
-328.6%45.8%
Fair Value Upside
Unlock14.2%8.6%Unlock

Earnings

Latest Release
Apr 03, 2025
EPS / Forecast
-16.92 / -0.15
Revenue / Forecast
-1,570,000.00 / --
EPS Revisions
Last 90 days

FAQ

What Is the Apollomics (APLM) Stock Price Today?

The Apollomics stock price today is 4.74

What Stock Exchange Does Apollomics Trade On?

Apollomics is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Apollomics?

The stock symbol for Apollomics is "APLM."

What Is the Apollomics Market Cap?

As of today, Apollomics market cap is 5.10M.

What Is Apollomics's Earnings Per Share (TTM)?

The Apollomics EPS (TTM) is -52.80.

From a Technical Analysis Perspective, Is APLM a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.